CSS
AGIO icon

Cubist Systematic Strategies’s Agios Pharmaceuticals AGIO Stock Holding History

Cubist Systematic Strategies’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$251K Buy
+6,264
New +$236K ﹤0.01% 2582
2024
Q1 		– Sell
-4,067
Closed -$90.6K – 3647
2023
Q4 		$90.6K Buy
+4,067
New +$91.1K ﹤0.01% 3194
2022
Q4 		– Sell
-46,593
Closed -$1.32M – 4200
2022
Q3 		$1.32M Buy
46,593
+35,806
+332% +$960K 0.01% 2378
2022
Q2 		$239K Buy
+10,787
New +$244K ﹤0.01% 3587
2022
Q1 		– Sell
-67,029
Closed -$2.2M – 3530
2021
Q4 		$2.2M Buy
67,029
+51,323
+327% +$2.07M 0.02% 1279
2021
Q3 		$725K Buy
15,706
+12,493
+389% +$604K 0.01% 1769
2021
Q2 		$177K Sell
3,213
-65,903
-95% -$3.69M ﹤0.01% 2605
2021
Q1 		$3.57M Sell
69,116
-7,017
-9% -$348K 0.05% 637
2020
Q4 		$3.3M Sell
76,133
-70,139
-48% -$2.77M 0.05% 664
2020
Q3 		$5.12M Buy
146,272
+142,311
+3,593% +$6.24M 0.08% 402
2020
Q2 		$212K Sell
3,961
-8,456
-68% -$392K ﹤0.01% 2002
2020
Q1 		$441K Buy
+12,417
New +$574K 0.01% 1320
2019
Q4 		– Sell
-57,675
Closed -$1.87M – 2392
2019
Q3 		$1.87M Buy
57,675
+38,039
+194% +$1.57M 0.04% 655
2019
Q2 		$979K Buy
+19,636
New +$1.05M 0.02% 1057
2019
Q1 		– Sell
-19,626
Closed -$905K – 2221
2018
Q4 		$905K Buy
19,626
+19,258
+5,233% +$1.19M 0.04% 609
2018
Q3 		$28K Sell
368
-782
-68% -$62.9K ﹤0.01% 1772
2018
Q2 		$97K Buy
1,150
+950
+475% +$82.8K ﹤0.01% 1543
2018
Q1 		$16K Buy
200
+100
+100% +$7.73K ﹤0.01% 1755
2017
Q4 		$6K Sell
100
-2,291
-96% -$144K ﹤0.01% 1862
2017
Q3 		$160K Sell
2,391
-1,032
-30% -$62K 0.01% 1523
2017
Q2 		$176K Buy
3,423
+3,123
+1,041% +$160K 0.01% 1333
2017
Q1 		$18K Sell
300
-366
-55% -$17.5K ﹤0.01% 1550
2016
Q4 		$28K Sell
666
-2,513
-79% -$132K ﹤0.01% 1620
2016
Q3 		$168K Sell
3,179
-7,969
-71% -$347K 0.01% 1329
2016
Q2 		$467K Buy
11,148
+6,319
+131% +$312K 0.03% 816
2016
Q1 		$196K Buy
+4,829
New +$206K 0.01% 1233
2014
Q4 		– Sell
-3,842
Closed -$236K – 1859
2014
Q3 		$236K Buy
+3,842
New +$166K 0.01% 1263

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Cubist Systematic Strategies's AGIO Position: Q3 2025 in Review

Cubist Systematic Strategies opened a new position in Agios Pharmaceuticals (AGIO) in Q3 2025: 6,264 shares worth $251K. The stake represents ﹤0.01% of the portfolio and ranks #2582 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in AGIO as recently as Q4 2023.

Cubist Systematic Strategies first reported a position in AGIO in Q3 2014 and has held it in 27 quarters since. The position peaked at $5.12M in Q3 2020. 221 funds tracked by Wall St. Rank hold AGIO as of Q3 2025.

  • Cubist Systematic Strategies held 6,264 shares of Agios Pharmaceuticals worth $251K as of Q3 2025.
  • Agios Pharmaceuticals was a new Cubist Systematic Strategies position in Q3 2025.
  • Agios Pharmaceuticals made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2582 holding.
  • Cubist Systematic Strategies first reported a position in Agios Pharmaceuticals in Q3 2014 and has held it in 27 quarters since.
  • Cubist Systematic Strategies's Agios Pharmaceuticals position peaked at $5.12M in Q3 2020.
  • 221 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.